KR101779671B1 - Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it - Google Patents
Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it Download PDFInfo
- Publication number
- KR101779671B1 KR101779671B1 KR1020150158363A KR20150158363A KR101779671B1 KR 101779671 B1 KR101779671 B1 KR 101779671B1 KR 1020150158363 A KR1020150158363 A KR 1020150158363A KR 20150158363 A KR20150158363 A KR 20150158363A KR 101779671 B1 KR101779671 B1 KR 101779671B1
- Authority
- KR
- South Korea
- Prior art keywords
- natural
- liposome
- extract
- saccharomyces cerevisiae
- emulsifier
- Prior art date
Links
- 229940041514 candida albicans extract Drugs 0.000 title claims abstract description 18
- 239000012138 yeast extract Substances 0.000 title claims abstract description 18
- 235000013305 food Nutrition 0.000 title claims abstract description 12
- 241000235070 Saccharomyces Species 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title description 4
- 239000002502 liposome Substances 0.000 claims abstract description 97
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000002904 solvent Substances 0.000 claims abstract description 22
- 239000003755 preservative agent Substances 0.000 claims abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 14
- 230000002335 preservative effect Effects 0.000 claims abstract description 11
- 229940075887 saccharomyces cerevisiae extract Drugs 0.000 claims abstract description 11
- 238000002525 ultrasonication Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000000470 constituent Substances 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000012153 distilled water Substances 0.000 claims description 24
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 20
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003963 antioxidant agent Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 239000008188 pellet Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 235000021313 oleic acid Nutrition 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 229940042880 natural phospholipid Drugs 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- 241000207199 Citrus Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 235000020971 citrus fruits Nutrition 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- 240000000560 Citrus x paradisi Species 0.000 claims 1
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 6
- 241000235088 Saccharomyces sp. Species 0.000 abstract description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 87
- 229960003180 glutathione Drugs 0.000 description 42
- 108010024636 Glutathione Proteins 0.000 description 37
- 230000036542 oxidative stress Effects 0.000 description 37
- 241000700159 Rattus Species 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 239000000523 sample Substances 0.000 description 23
- 230000003078 antioxidant effect Effects 0.000 description 19
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 102000019197 Superoxide Dismutase Human genes 0.000 description 15
- 108010012715 Superoxide dismutase Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000005228 liver tissue Anatomy 0.000 description 9
- 102000016938 Catalase Human genes 0.000 description 8
- 108010053835 Catalase Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- -1 lipid peroxide Chemical class 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000037384 skin absorption Effects 0.000 description 3
- 231100000274 skin absorption Toxicity 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-L 5-[(3-carboxylato-4-nitrophenyl)disulfanyl]-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)[O-])=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C([O-])=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-L 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229940065115 grapefruit extract Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229920006280 packaging film Polymers 0.000 description 2
- 239000012785 packaging film Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940079877 pyrogallol Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 101710170157 Glutathione hydrolase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- RWSXRVCMGQZWBV-UHFFFAOYSA-N L-Glutathione (reduced) Chemical compound OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000877401 Saccharomyces ellipsoideus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000002338 electrophoretic light scattering Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
- A23L33/145—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
-
- C12R1/865—
Abstract
The present invention includes a first step of mixing at least one natural emulsifier with a natural-derived solvent and ultrasonication, a second step of adding a saccharomyces sp. Yeast extract as a capturing substance to the product of the first step and ultrasonication A liposome constituent substance containing a natural preservative, and a natural liposome containing a Saccharomyces cerevisiae extract as a capturing substance, a process for producing the same, and a process for producing the same, Thereby providing a food or pharmaceutical composition.
Description
The present invention relates to a natural liposome containing a yeast extract of Saccharomyces sp., A method for producing the same, and a food or a pharmaceutical composition containing the same. More specifically, the present invention relates to a natural liposome which provides antioxidant, And a food or pharmaceutical composition containing the same.
As the eating habits of modern people gradually become westernized and the stress increases, there is a growing interest in antioxidants that can prevent the oxidative stress of the human body. As body activity increases, the body's oxygen consumption increases, resulting in increased free radical production due to oxidative stress [1].
There is a proper antioxidant system in the body that can treat active oxygen under physiological conditions. The antioxidant system is largely composed of enzymatic antioxidant groups including glutathione peroxidase (GPX) and catalase (CAT), and glutathione, which are highly intracellular antioxidant enzymes such as superoxide dismutase (SOD), glutathione peroxidase , Non-enzymatic antioxidant groups including vitamin C, vitamin E, carotenoids, and uric acid [2].
Glutathione (γ-glutamyl-cysteinyl-glycine (GSH)) acts not only on various enzymatic or nonenzymatic detoxification mechanisms, but also on free radical scavenging activity, And xenobiotics. ≪ / RTI > In addition, the kidneys, liver, lungs, small intestine and many other organisms that can be exposed to water can protect the body.
However, glutathione (GSH) has a low cellular uptake rate, is unstable in a neutral or alkaline environment, and has low bioavailability. This is because the thiol groups of glutathione (GSH) are easily oxidized to GSSG under oxidative stress. Therefore, there is an urgent need to develop a technique for preventing oxidation of glutathione (GSH).
To solve this problem, many studies have been conducted to protect glutathione from enzymatic damage. For example, nanoparticles containing glutathione, encapsulation, chitosan coating, and packaging films have been developed. Japanese Laid-Open Patent Publication No. 2013-0137561 discloses a method for producing a food packaging film having improved glutathione stability. However, liposomes made of natural substances, foods containing them or pharmaceutical compositions are not known at all.
Particularly, liposomes are biocompatible because they are composed of phospholipid, which is a main component of a vital cell membrane, and can store desired substances (drugs, nutrients, etc.) in a bilayer structure, so that unstable and difficult- There are advantages. However, in spite of these advantages, liposomes are unstable in formulation, have a low collection efficiency, and also have a problem that solvents and preservatives used in the production of liposomes cause skin irritation.
Disclosure of the Invention An object of the present invention is to provide a natural liposome which is easy to absorb in the body while alleviating oxidative stress, and an antioxidant food or pharmaceutical composition containing the same.
One embodiment of the present invention includes a first step of mixing at least one natural emulsifier with a natural-derived solvent and ultrasonication, adding a yeast extract of Saccharomyces genus as a capturing substance to the product of the first step, Wherein the natural liposome comprises at least one natural emulsifier, a natural-derived solvent, a liposome constituent material containing a natural preservative, and a natural liposome comprising Saccharomyces cerevisiae extract as a capturing agent, to provide.
Another embodiment of the present invention provides a food composition or a pharmaceutical composition containing the natural liposome as an active ingredient.
In another embodiment of the present invention, there is provided a method for producing a microorganism, comprising the steps of mixing at least one natural emulsifier with a natural solvent, and then ultrasonically treating the mixture at 50 to 80 ° C .; adding a Saccharomyces cerevisiae extract to the product of the first step And a third step of adding a distilled water heated to 40 to 60 ° C. to the product of the second step and a natural preservative and ultrasonically treating the product to form a liposome. to provide.
The natural liposome containing the Saccharomyces cerevisiae extract according to the present invention can increase the glutathione absorption capacity in the intestines upon oral ingestion. In addition, the food or pharmaceutical composition containing the natural liposome according to the present invention may exhibit excellent antioxidative and fatigue recovery effects.
1 shows a process for producing a natural liposome according to an embodiment of the present invention.
Fig. 2 shows the results of the analysis of the glutathione content according to the kind of yeast and the treatment method.
3A, 3B, and 3C are electron micrographs of the extract of Comparative Example 1, the liposome of Example 1, and the liposome of Comparative Example 2, respectively.
Figs. 4A, 4B, and 4C show particle distributions of the extract of Comparative Example 1, the liposome of Example 1, and the liposome of Comparative Example 2, respectively, by a laser particle size analyzer.
Fig. 5 shows the results of the skin absorption test of the extract of Comparative Example 1, the liposome of Example 1, and the liposome of Comparative Example 2. Fig.
6 shows the cytotoxicity test results of the extract of Comparative Example 1 and the liposome of Example 1. Fig.
Figure 7 shows the cell survival rate during oxidative damage of each sample.
Figure 8 shows the intracellular SOD activity of each sample.
Figure 9 shows the Rat spleen index of each sample.
Figure 10 shows erythrocyte SOD activity for Rat of each sample.
Figure 11 shows erythrocyte catalase activity for Rat of each sample.
Figure 12 shows the intrathecal glutathione content for Rat of each sample.
Figure 13 shows the content of liver glutathione hydrolase relative to Rat of each sample.
Figure 14 shows the intrahepatic lipid peroxide content for Rat of each sample.
15 shows a liver tissue photograph of Rat of each sample.
Figure 16 shows the AST content in the Rat serum of each sample.
Figure 17 shows the ALT content in the Rat serum of each sample.
Figure 18 shows the CPK content in Rat serum of each sample.
Figure 19 shows the LDH content in Rat serum of each sample.
Figure 20 shows the antioxidant content in Rat serum of each sample.
Figure 21 shows the antioxidative effect of each sample in Rat serum.
Hereinafter, natural liposomes containing Saccharomyces cerevisiae extract according to the present invention will be described in detail with reference to the accompanying drawings.
However, these descriptions are provided only to illustrate the present invention, and the scope of the present invention is not limited by these exemplary explanations.
1. Natural Emulsifier
Natural emulsifiers are substances that constitute the lipid bilayer and emulsifiers derived from natural materials. The natural emulsifiers include phospholipids and fatty acids. The phospholipids contained in the natural emulsifiers are natural phospholipids derived from natural origin, and fatty acids are natural fatty acids derived from natural sources.
Examples of the phospholipid include phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, or their hydrogenation products (for example, phosphatidylserine, phosphatidylglycerol, , Hydrogenated phophatidylcholine (derived from soybean), etc.) may be used. Hydrogenerated phosphatidylcholine, which is preferably excellent in oxidation stability, may be used.
Examples of the fatty acid include at least one natural fatty acid selected from the group consisting of palmitic acid, stearic acid, oleic acid, linoleic acid, and linolenic acid (derived from soybean) Can be used.
The natural emulsifier may comprise from 70 to 90% by weight of natural phospholipids and from 1 to 5% by weight of natural fatty acids based on the weight of the total natural emulsifier. Other solvent may be contained in the remaining amount. As the solvent, it is preferable to use a naturally derived solvent, and it is more preferable to use distilled water.
Natural emulsifiers can be used in combination of two or more kinds. For example, two kinds of natural emulsifiers or three kinds of natural emulsifiers may be mixed and used. When two natural emulsifiers are mixed and used, for example, the first natural emulsifier may be selected from the group consisting of phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, palmitic acid, stearic acid stearic acid, oleic acid, linoleic acid and linolenic acid (derived from soybean), and the second natural emulsifier may be hydrogenated phosphatidylcholine (derived from soybean) . In addition, when three natural emulsifiers are mixed and used, for example, in addition to the first natural emulsifier and the second natural emulsifier, a third natural emulsifier such as cetearylolivate, sorbitanolivate- Olive) can be used.
2. Collecting material
Saccharomyces cerevisiae may be used as a trapping substance that can be trapped in the phospholipid layer of the liposome, for example, Saccharomyces cerevisiae cerevisiae ), Saccharomyces ellipsoideus ), Saccharomyces ( Saccharomyces carlsbergenis ) may be used. Preferably, Saccharomyces cerevisiae can be used, most preferably Saccharomyces cerevisiae cerevisiae MAB Y1 (KCTC 11386BP) may be used.
As the capturing material, it is preferable to use the yeast extract. It is particularly preferable to use an ultrasonicated yeast extract.
In general, yeast extract contains a large amount of nucleic acid and protein, which are tastes, and is widely used as a natural flavor ingredient. The tripeptide glutathione (L-glutamyl-L-cysteinylglycine) among the tastes of the yeast extract provides taste persistence. Glutathione present in yeast is a reduced form that is present in the cells of microorganisms, animals and plants, and has antioxidative effects against oxidative damage, and provides various pharmacological effects such as improvement of liver disease, treatment of diabetes, and anticancer activity Also known.
The yeast extract may be a supernatant obtained by disrupting cells or cells by ultrasonication, or a mixture thereof may be used at a certain ratio. It is more preferred to use a supernatant. When the yeast extract is produced through ultrasonic disruption, it is preferable that the antioxidant component is prevented from destruction, the extract can be obtained in a short time, and the process is relatively simple. The content of the capturing material is 1 to 50% by weight based on the weight of the whole natural liposome.
3. Solvent
Examples of the solvent include natural solvents such as distilled water, glycerin from natural origin, butylene glycol from natural origin, propylene glycol from natural origin, natural ethanol, natural propanediol, natural glycerin, fermented alcohol, , Natural-derived glycerin, natural ethanol, and more preferably distilled water. The content of the solvent is the residual amount of the emulsifier, the trapping agent, and the preservative.
4. Preservatives
Preservatives may be any natural preservatives that can be used as food preservatives. For example, natural extracts can be used. Preferably, grapefruit extract, citrus extract may be used. It is distinguished from benzoic acid, sorbic acid, propionic acid, dehydroacetic acid, paraoxybenzoic acid and the like which are commonly used preservatives in that they are natural extracts. The preservative may comprise from 0.1 to 5% by weight, based on the total weight of the natural liposome.
5. Preparation of liposome
The liposome according to the present invention can be produced using ultrasonic waves. The specific manufacturing method is as follows.
One or more natural emulsifiers are mixed with a part of a natural solvent and homogenized by ultrasonic disruption at 50 to 80 degrees Celsius using an ultrasonic liquid processor. When the natural emulsifier is homogenized, it is mixed with ultrasonic wave after addition of the capturing material. Homogenization of the emulsifier and the collecting material can be enhanced and the particle size can be controlled by ultrasonic disintegration in the step of homogenizing the natural emulsifier and the step of adding the collecting material, unlike the prior art using the homogenizer and the like. When the emulsifier and the collecting material are completely homogenized, distilled water and natural extract (preservative) heated to 40 to 60 degrees Celsius are added and mixed with ultrasonic waves to form liposome type particles. Thereafter, the temperature is gradually lowered and ultrasonication is finally performed for 5 minutes to make the particles smaller and uniform so that a natural liposome is finally produced. The manufacturing process is shown in Fig.
The natural liposome according to an exemplary embodiment of the present invention is distinguished from conventional synthetic liposomes in that it does not contain a synthetic component, including natural emulsifiers, natural solvents, natural preservatives, and naturally occurring components.
Further, the liposome according to the present invention can improve the absorption rate by increasing the transmissivity in the body, and can effectively function as a food composition or a pharmaceutical composition. The liposome according to the present invention can be used in the form of beverage, health functional food, and the like.
<Selection of raw yeast - Analysis of glutathione content according to treatment method>
The contents of glutathione in microorganisms were checked and the contents of glutathione were analyzed according to the treatment method to select appropriate raw materials. For this purpose, Saccharomyces cerevisiae cerevisiae MAB Y1 (KCTC 11386BP) was cultured at 30 占 폚 in a
0.6 ml of DTNB (5'-dithiobis (2-nitrobenzoic acid)) color development reagent was added to 0.5 ml of the microbial crush supernatant and diluted with the same amount of distilled water. After reacting for 15 minutes, absorbance was measured at 412 nm. The glutathione content was calculated from the standard calibration curves of glutathione.
In order to select an appropriate yeast extract, in addition to the glutathione content of the supernatant of the microorganism, the glutathione content of the cells, the glutathione content of the ultrasonic disruption pellet, the pellet / supernatant when disrupted using ethanol instead of ultrasonic disruption Glutathione content in the culture medium, glutathione content in the culture medium, and glutathione content in the yeast fermentation powder were measured. The results are shown in FIG.
As a result, as shown in FIG. 2, the content of glutathione in supernatant of supersonic wave was the highest at 1.29 mg / ml. Thus, supernatant supernatant was used for the preparation of Y1 extract.
< Example 1>
<Preparation of Y1 extract>
Mrs. serenity in a busy Saccharomyces (Saccharomyces cerevisiae) MAB Y1 (the resulting rice wine yeast), were cultured for 72 hours in accordance with the culture conditions shown in Table 1 below in a medium containing glucose (Glucose), salt (NaCl), Taurine.
The cultured microbial culture broth (Y1 culture broth) was centrifuged to collect cells, and 30 g of distilled water was added to 3 g of the recovered microbial cells, followed by sonication. It was then centrifuged at 3,000 rpm for 10 minutes to obtain a shredded pellet and a supernatant. Here, the pellet was removed and the supernatant was recovered, and this supernatant was used as a MAB Y1 extract (Y1 extract) in Saccharomyces cerevisiae as a capturing substance. Ultrasonic processing was carried out at 10 Amp for 10 minutes.
< Sakaromisses Serenity busy (Saccharomyces cerevisiae ) Manufacture of Natural Liposomes Containing MAB Y1>
(3% by weight of palmitic acid, 1% by weight of stearic acid, 3% by weight of oleic acid, and 7% by weight of linoleic acid) based on 100% by weight of the total amount of natural emulsifier (phosphatidylcholine 67% by weight, lysophosphatidylcholine 8% by weight, phosphatidylethanolamine 8% %,
≪ Example 2 >
A natural liposome was prepared in the same manner as in Example 1, except that the content of Y1 extract was 20% by weight and distilled water was used as the remaining amount.
≪ Example 3 >
A natural liposome was prepared in the same manner as in Example 1, except that the content of Y1 extract was 10% by weight and distilled water was used as the remaining amount. Table 2 shows the raw materials and their contents used in Examples 1 to 3 above.
(Emulsification process)
( Saccharomyces cerevisiae )
≪ Comparative Example 1 &
In Comparative Example 1, 30% by weight of the Y1 extract used as the capturing material instead of the natural liposome of Example 1 and the remaining amount of distilled water were mixed and used.
≪ Comparative Example 2 &
In Comparative Example 2, a conventional synthetic liposome containing Y1 extract, lecithin, cholesterol, glycerin, and potassium sorbate was prepared.
Distilled water (30% by weight) was used as a solvent. Phospholipid (lecithin-1%), synthetic cholesterol (0.2% by weight) and synthetic glycerin (1% by weight) were mixed and heated to 65 占 폚. When the phospholipid was completely dissolved, the same amount of Y1 extract as in Example 1 was added and homogenized with a homogenizer. The remaining water was mixed with an antiseptic agent (potassium sorbate 0.1%) to form liposome particles, and the particles were homogenized through ultrasonic treatment.
<Experimental Example 1> Analysis of morphology and size of liposome by electron microscope
The shape and size of the Y1 extract of Comparative Example 1, Y1 natural liposome (Y1 CPS) of Example 1 and Y1 synthetic liposome of Comparative Example 2 were analyzed using a scanning electron microscope (Scanning Electron microscope S-1700, Hitachi) . The results are shown in Figs. 3A, 3B and 3C, respectively.
EXPERIMENTAL EXAMPLE 2 Analysis of Size of Liposome by Laser Particle Size Analyzer
The particle size of the sample was measured and the particle size distribution was analyzed using a laser particle size analyzer (Electrophoretic Light Scattering Spectrophotometer ELS-8000, Otsuka). The average particle sizes of the Y1 extract of Comparative Example 1, the Y1 natural liposome of Example 1 (Y1 CPS) and the Y1 synthetic liposome of Comparative Example 2 are shown in Table 3 below.
4A, 4B and 4C show particle distributions of the Y1 extract of Comparative Example 1, Y1 natural liposome of Example 1 (Y1 CPS) and Y1 synthetic liposome of Comparative Example 2, respectively.
<Experimental Example 3> Measurement of collection rate
2 ml of the resultant Y1 natural liposomal suspension was taken and a 0.45 쨉 m to 25 mm syringe filter (GVS, USA) was attached to a 10 ml syringe to remove non-captured liposomal substances. The removed portion was supplemented with distilled water, and the absorbance was measured at the maximum absorption wavelength of the Y1 extract. The collection rate of the collected Y1 extract was confirmed by substituting the following equation.
Entrapment efficiency (%) = Y e / Y i x 100 (%)
Y e : the concentration of the entrapped substance (encapsulated concentration)
Y i : initial concentration of the whole substance
The collection rates are shown in Table 4 below.
As a result of measuring the percentages of the natural liposome of Example 1 and the synthetic liposome of Comparative Example 2, the percentages of the Y1 natural liposomes (98.11%) of Example 1 were higher than those of the synthetic liposome of Comparative Example 2 (89.02%).
<Experimental Example 4> Skin absorption using Franz Diffusion cell
In order to examine the effect of the prepared Y1 natural liposome on skin permeation enhancement, a skin permeation experiment was conducted using an in vitro permeation experiment (Franz Diffusion cell). In the experiment, chicken skin tissue was used to remove hair. The absorption of the same amount of Y1 extract, Y1 natural liposome and Y1 synthetic liposome was compared. The chicken skin was fixed between the donor and receptor phases, and 1 ml of sample was added to the donor of the prepared Franz diffusion cell, and the temperature was maintained at about 36.5 ° C in a constant temperature water bath. At the time of 0 hour, 1 hour, 3 hours and 6 hours, 0.25 ml of receptor phase was recovered and the same amount of distilled water was supplied.
Fig. 5 shows the results of comparing the skin absorption tests of the Y1 extract of Comparative Example 1, the Y1 natural liposome of Example 1, and the Y1 synthetic liposome of Comparative Example 2. As shown in FIG. 5, the absorption power of the Y1 extract (Y1) of Comparative Example 1 was the lowest and the absorption power of the Y1 natural liposome (Y1 CPS) of Example 1 was the highest.
[Cell Experiment]
<Experimental Example 5> Cytotoxicity using MTT
Fibroblast cells (1 × 10 5 ) were dispensed into 48 wells. After 24 hours, the cells were replaced with fresh medium, and the samples were treated for 0.05 to 1% concentration for 24 hours. Subsequently, 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (0.1 mg / ml) was added to each well and incubated for 3 hours. Insoluble formazan formed was dissolved in 0.04 N HCl / isopropanol And absorbance was measured at 570 nm through an ELISA reader.
As shown in FIG. 6, the cytotoxicity of the Y1 natural liposome (Y1 CPS) of Example 1 was lower than that of the Y1 extract of Comparative Example 1 at a concentration of 0.25% Was higher.
<Experimental Example 6> Recovery effect of oxidative damage
1 × 10 5 keratinocyte HaCaT cells were plated in 48 wells, replaced with fresh medium after 24 hours, and treated for 24 hours. To induce oxidative stress, 500 uM H2O2 was treated for 4 hours and then 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (0.1 mg / After incubation, insoluble formazan formed was dissolved in 0.04 N HCl / isopropanol and the absorbance at 570 nm was measured by ELISA reader.
The keratinocytes were treated with hydrogen peroxide to induce oxidative stress, and the test material was treated to confirm cell viability. The results are shown in FIG.
As shown in FIG. 7, the cell survival rate of the group treated with hydrogen peroxide was only 77.9% of the cell survival rate of the group not treated with hydrogen peroxide. On the other hand, when the Y1 natural liposome of Example 1 was treated, the cell viability increased to 85.7%.
<Experimental Example 7> Intracellular SOD activity
Peroxidase (SOD) is an enzyme that catalyzes the conversion of excess oxidized ions to oxygen and hydrogen peroxide. The peroxidase-eliminating enzyme is known to act as an antioxidant defense mechanism in almost all cells exposed to oxygen, and is a typical antioxidant that inhibits active oxygen.
Dermal cells in 48 wells Human dermal fibroblast (HDF) cells were dispensed at 1 × 10 5 cells, replaced with fresh medium after 24 hours, and treated for 24 hours. Then, the cells were collected and cell lysate was used for the experiment.
SOD activity was measured by measuring the absorbance at 420 nm using a UV / VIS spectrophotometer (UV-2401PC, Shimadzu) as a method for measuring the amount of inhibition of the auto-oxidation of pyrogallol. The activity of enzyme was calculated by converting the color development of pyrogallol into% SOD activity based on normal cells not treated with H2O2. The results are shown in Fig.
As shown in FIG. 8, it was confirmed that SOD activity was lowered to 20% by treatment with hydrogen peroxide in skin dermal cells. SOD activity was increased when the cells were treated with an antioxidant (Ascorbic acid (AA), BHT). SOD activity was increased to 51.652% by the Y1 natural liposome treatment of Example 1.
[Animal experiment]
<Experimental Example 8> Oxidative stress-improving effect on t-BHT-induced Rat
Experimental animals and oxidative induction
SD Rat was used for the experiment and 4 week old male rats weighing 130g were received from BioLink (Chungcheongbuk - do, Korea) and underwent a treatment period of 4 weeks after the adaptation period of 1 week. During the test period, feed and water were freely taken, and the temperature of the breeding room (22 ± 2), relative humidity (55 ± 5%) and intensity were maintained for 12 hours. Oxidative stress was induced by injecting t-butyl hydroperoxide (t-BHT) 0.5 mmol / kg into the peritoneal cavity of the rats on the last day of the experiment.
<Experimental Example 9> Spleen index comparison of Rat causing oxidative stress
For immunological evaluation, the spleen was sacrificed at the end of the experiment and the weight was measured. The results are shown in the graph of FIG. The spleen index was expressed as the ratio of the spleen weight (mg) to the weight (g) of the mouse.
As shown in FIG. 9, the spleen index was 2.54 mg / g in the normal group which did not induce the oxidative stress but the spleen index increased to 2.74 mg / g in the group that caused the oxidative stress Respectively. In the case of treatment with the natural liposome (Y1 CPS) of Example 1, it was 2.35 mg / g, which was the most similar to that of the normal group. These results suggest that the natural liposome of Example 1 significantly inhibited the increase of T lymphocytes in the spleen.
<Experimental Example 10> Comparison of SOD activity of erythrocytes of Rat causing oxidative stress
After collecting blood of Rat causing oxidative stress, red blood cells were collected and used in the experiment. For pretreatment, add 0.9 ml of 10 mM Tris-1 mM EDTA buffer to 100 μl of red cell suspension, add 0.4 ml of Chloroform-Ethanol solution and mix for 2 minutes, then add 140ul of tertiary distilled water and centrifuge at 20,000g at 4 ℃ for 30 minutes The supernatant was used for the experiment.
SOD activity in erythrocytes was determined based on SOD activity in erythrocytes of normal group which did not induce oxidative stress. The results are shown in Fig.
As shown in FIG. 10, the SDO activity of erythrocytes in the control group treated with only t-BHT decreased to 43.7%. On the other hand, in the group administered with Y1 natural liposome of Example 1, 77.8% of the SOD activity showed the closest activity to the normal group which did not induce oxidative stress.
Experimental Example 11: Comparison of erythrocyte catalase activity of oxidative stress induced Rat
Catalase activity of erythrocytes recovered from blood of Rat causing oxidative stress was measured. Pretreatment was performed by adding 1.35 ml of 10 mM Tris-1 mM EDTA buffer to 150 μl of a red cell suspension, and then diluting the solution 1000 times with 0.01 M phosphate buffer (pH 7.4). Then 15ml tube to 250mM KH 2 PO 4 -NaOH buffer ( pH 7.0) 300ul, into a 100% methanol 300ul, 0.27% H2O2 60ul was added 600ul of the sample was reacted at 20
Catalase activity was 122.77 nmol in the normal group that did not induce oxidative stress and 119.18 nmol in the control group that induced oxidative stress by t-BHT. Respectively.
In contrast, the catalase activity in the erythrocytes treated with the natural liposome (Y1 CPS) of Example 1 was 123.16 nmol, which was similar to that of the normal group, although it induced oxidative stress. That is, it was found that catalase activity did not decrease due to oxidative stress.
EXPERIMENTAL EXAMPLE 12 Comparison of Glutathione Content in Liver of Rat Induced by Oxidative Stress
To 0.2 ml of homogenate fraction of liver tissue, 0.3 ml of tertiary distilled water and 0.5 ml of 0.4% sulfosalicylic acid were added and mixed. After centrifugation, 5'-dithiobis (2-nitrobenzoic acid) (DTNB) coloring reagent was added to 0.3 ml of supernatant And the absorbance at 412 nm was measured. The glutathione content was calculated from the standard calibration curves of glutathione and expressed in ml per mg of liver tissue. The results are shown in Fig.
As shown in FIG. 12, the content of glutathione was 0.746 mg / ml in the normal group but 0.737 mg / ml in the control group, indicating that the content of glutathione decreased when oxidative stress was induced I could confirm. On the other hand, it was confirmed that the glutathione tends to increase in the extract (Y1) of Comparative Example 1, the natural liposome (Y1 CPS) of Example 1 and the synthetic liposome of Comparative Example 2 (Y1 synthetic liposome) The glutathione content of liposomes (Y1 CPS) was the highest at 0.772 mg / ml.
< Experimental Example 13> Oxidative In the liver of stress-induced rats Glutathione Comparison of hydrolytic enzyme content
Glutathione (GSH) -Px is an antioxidant enzyme with selenium, which is involved in the detoxification of peroxidized lipids and H2O2 using glutathione (glutathione (GSH)) present in the body as a substrate. In case of deficiency of iron, vitamin E and essential fatty acids It is reported that the activity is decreased and the activity is increased by oxidative stress.
To measure the amount of GSH-Px in liver tissue, 100ul of tissue fluid was added to 96 wells and 100ul of GPX buffer mixture (2mM NADPH, 4mM reduced glutathione, 25.6mU / ml glutathione reductase, 5mM EDTA, 50mM Tris, Respectively. 50 ul of GPx Substrate Mic (16 mM hydrogen peroxide) was added and the absorbance was measured at 340 nm for 10 minutes at intervals of 1 minute. The results are shown in Fig.
The GSH-px of 13.73 Unit / ml was measured in the normal group which did not induce oxidative stress and the GSH-px content of 26.47Unit / ml in the group which induced oxidation by t-BHT Showed that the content of GSH-px was increased when oxidative stress was induced. On the other hand, the Y1 natural liposome of Example 1 showed GSH-px of 15.13 Unit / ml, which was similar to that of the normal group.
< Experimental Example 14> Oxidative Liver lipid peroxidation in stressed rats MDA ) Content comparison
Peroxide lipid content (MDA) of the homogenate fraction from liver tissue was measured by TBARS method. 2 ml of TBA (thiobarbituric acid) reagent was added to 1 ml of the fraction solution containing 1 mg of protein, followed by 30 minutes of reaction in boiling water, followed by cooling at room temperature, centrifugation at 3,000 rpm for 10 minutes, nm absorbance was measured. The results are shown in Fig.
As a result, the content of lipid peroxidation was 75.87 nmol / ml in the normal group and 77.16 nmol / ml in the control group causing oxidative stress. As a result, it was confirmed that the content of lipid peroxide in the Y1 natural liposome of Example 1 was remarkably low.
EXPERIMENTAL EXAMPLE 15 Histological Evaluation of Rat Induced Oxidative Stress
Liver tissues were examined to determine the effect of oxidative stress on the liver tissue of Rat. A portion of the liver tissue was fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin-eosi (H & E). The results are shown in Fig. Histologic observation showed that in the normal group without oxidative stress, liver tissue was constant, while in the control group injected with t-BHT, cell tissue was damaged and pores were formed. In the case of the group treated with the natural liposome (Y1 CPS) of Example 1, it was confirmed that the arrangement of the cells was constantly restored similar to that of the normal group.
<Experimental Example 16> Biochemical indicators of oxidative stress induced Rat serum
The AST, ALT, CPK total (S) and LDH contents in the serum were analyzed and the results are shown in FIGS. 16 to 19, respectively.
The levels of AST and ALT, the enzymes secreted by liver injury, were the lowest in the normal group without oxidative stress. On the other hand, in the group treated with t-BHT, it was confirmed that the value was increased. It was confirmed that the content of the enzyme decreased in the group treated with the natural liposome (Y1 CPS) of Example 1 (Figs. 16 and 17).
The contents of creatine kinase (CPK) and lactate dehydroxygenase (LDH) were analyzed to analyze serum fatigue substances. As a result of the analysis, it was confirmed that the CPK value of the CPK was increased in the control group that caused the oxidative stress when compared with the normal group, and that of the natural liposome (Y1 CPS) of Example 1 was 308 U / L. In addition, the LDH content was also found to be 245 U / L in the normal group and 393 U / L in the oxidation-induced control group. As a result, it was confirmed that the LDL value increased and the natural liposome Y1 CPS) treated group showed an LDH content of 228.33 U / L, which is similar to that of the normal group, even though oxidative stress was induced (FIGS. 18 and 19).
<Experimental Example 17> Antioxidant analysis of serum induced by oxidative stress
To determine the antioxidant activity in the serum, vitamin C content of the sera isolated from the blood was analyzed. The content of VitaminC was determined by adding 2 ml of 5% TCA (Trichloroacetic acid) to 0.5 ml of the sample, precipitating the protein, centrifuging and adding color development reagent (85% orthophosphoric acid 0.05 ml + 8% a, a'-Bipyridyl 0.05 ml + % aqueous ferric chloride 0.05ml) was added to the wells and incubated at 25 ° C for 1 hour to confirm formation of ferrous dipyridyl chromophore. Absorbance was measured at 525 nm using a UV spectrophotometer. The results are shown in Fig.
In the normal group, the content of 34.66 ug / ml was measured, and in the control group, the concentration was decreased to 22.23 ug / ml. On the other hand, in the case of the natural liposome (Y1 CPS) of Example 1, 31.98 ug / ml was recovered to a level similar to that of the normal group.
<Experimental Example 18> Antioxidant activity of serum of Rat causing oxidative stress
DPPH scavenging ability was confirmed to confirm antioxidative capacity in serum. The DPPH solution was prepared by dissolving 16 mg of DPPH in 100 ml of ethanol, mixing 100 ml of distilled water, and filtering through a filter paper. 0.5 ml of the sample solution was mixed with 2.5 ml of DPPH solution, and reacted at room temperature for 30 minutes. Absorbance was measured at 528 mm on a spectrophotometer (HITACHIU-2990). The DPPH free radical scavenging activity was expressed as a percentage (%) of absorbance difference between the sample and the non-additive. The results are shown in Fig.
Free radical scavenging activity in serum was 71.32% in normal group and 67.55% in control group, which caused oxidative stress. In the group treated with the sample other than the natural liposome (Y1 CPS) of Example 1, the control value was similar to that of the control, and the radical scavenging ability was not restored. On the other hand, in the group treated with the natural liposome (Y1 CPS) of Example 1, the radical scavenging ability was increased up to 70.21% and the oxidative stress was restored to a level similar to that of the normal group.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the invention. The present invention is not limited to the drawings.
Claims (19)
One or more natural emulsifiers, a natural derived solvent, a liposome constituent material containing a natural preservative,
A saccharomyces cerevisiae extract as a capturing substance,
Wherein the natural derived solvent is at least one selected from the group consisting of distilled water, butylene glycol, propylene glycol, propanediol, glycerin, ethanol, and fermented alcohol.
The Saccharomyces cerevisiae extract is a natural liposome that is a yeast extract of Saccharomyces cerevisiae .
The Saccharomyces cerevisiae extract is a natural liposome which is a yeast extract of Saccharomyces cerevisiae MAB Y1 (KCTC 11386BP).
The Saccharomyces cerevisiae extract is a natural liposome, which is an ultrasonically pulverized yeast extract.
Wherein the natural emulsifier comprises at least one natural phospholipid selected from the group consisting of phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, and their hydrogenation products.
Wherein the natural emulsifier comprises at least one naturally occurring fatty acid selected from the group consisting of palmitic acid, stearic acid, oleic acid, linoleic acid, and linolenic acid.
The natural preservative is a natural liposome, which is a natural-derived extract containing grapefruit or citrus extract.
The solvent is distilled water.
Wherein said natural emulsifier comprises a first natural emulsifier containing at least one fatty acid and at least one phospholipid and a second natural emulsifier containing at least one phospholipid.
Wherein the second natural emulsifier is at least one emulsifier selected from the group consisting of sorbitan olivate and cetearyl olivate.
Wherein the natural liposome comprises 2 to 9% by weight of a natural emulsifier based on the total weight of the natural liposome, 1 to 5% by weight of a natural preservative, 0.01 to 5% by weight of an extract of Saccharomyces cerevisiae and 0.01 to 5% by weight of a solvent.
Natural liposomes for antioxidants.
A second step of adding a Saccharomyces cerevisiae yeast extract to the product of the first step,
Adding a distilled water warmed at 40 to 60 ° C to the product of the second step and a natural preservative and sonicating to form a liposome;
13. The method according to any one of claims 1 to 6, 8 to 13, wherein the natural liposome is a liposome.
The fourth step of performing ultrasonic processing while gradually lowering the temperature after the third step
≪ / RTI >
Prior to the second step,
Saccharomyces cerevisiae, a makgeolli-derived yeast, cerevisiae ) MAB Y1,
The culture solution is centrifuged to collect the cells and subjected to ultrasonic treatment to obtain saccharomyces yeast extract
≪ / RTI >
After the ultrasonic treatment, centrifuging the ultrasonic treated cells again, removing the pellet, and recovering the supernatant
≪ / RTI >
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150158363A KR101779671B1 (en) | 2015-11-11 | 2015-11-11 | Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150158363A KR101779671B1 (en) | 2015-11-11 | 2015-11-11 | Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170055327A KR20170055327A (en) | 2017-05-19 |
KR101779671B1 true KR101779671B1 (en) | 2017-09-19 |
Family
ID=59049490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150158363A KR101779671B1 (en) | 2015-11-11 | 2015-11-11 | Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101779671B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107223953B (en) * | 2017-06-16 | 2019-12-17 | 盐城顶益食品有限公司 | Stable phosphatidylserine micro powder for food and preparation method thereof |
KR102448457B1 (en) * | 2019-07-10 | 2022-09-28 | 한국식품연구원 | Method for producing Saccharomyces cerevisiae extract using ultrasonication having potent inhibiting activity for skin cancer and composition for inhibiting skin cancer comprising the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100603814B1 (en) | 2004-03-11 | 2006-07-25 | 바이오스펙트럼 주식회사 | Nano liposome composition |
KR101503492B1 (en) * | 2013-07-03 | 2015-03-19 | 전북대학교산학협력단 | Liposomes capsule containing lipid and lysosomal enzymes, and manufacturing method thereof |
-
2015
- 2015-11-11 KR KR1020150158363A patent/KR101779671B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100603814B1 (en) | 2004-03-11 | 2006-07-25 | 바이오스펙트럼 주식회사 | Nano liposome composition |
KR101503492B1 (en) * | 2013-07-03 | 2015-03-19 | 전북대학교산학협력단 | Liposomes capsule containing lipid and lysosomal enzymes, and manufacturing method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20170055327A (en) | 2017-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nagai et al. | Preparation and functional properties of extracts from bee bread | |
Pandey et al. | Protective effect of resveratrol on markers of oxidative stress in human erythrocytes subjected to in vitro oxidative insult | |
Yurkiv et al. | Antioxidant effects of medicinal mushrooms Agaricus brasiliensis and Ganoderma lucidum (higher Basidiomycetes): evidence from animal studies | |
KR101779671B1 (en) | Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it | |
KR101876911B1 (en) | Cosmetic composition for anti-wrinkle and moisturizing effect comprising extract of Auricularia auricula as effective component | |
Latorres et al. | Nanoencapsulation of white shrimp peptides in liposomes: Characterization, stability, and influence on bioactive properties | |
US20140141066A1 (en) | Encapsulated Ascorbic Acid Composition | |
WO2006097627A1 (en) | Spirulin composition rich in active principles, method for obtaining same and use thereof | |
KR20180008179A (en) | Natural liposome comprising red yeast rice, process for the preparation thereof, and food or pharmaceutical composition comprising the same | |
KR101794419B1 (en) | Osmotic enzyme fermentation natural liposome containing mushroom, process for the preparation thereof, and cosmetic, food or pharmaceutical composition comprising the same | |
KR101737627B1 (en) | Antioxidant composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
KR101750616B1 (en) | Natural liposome comprising red ginseng, process for the preparation thereof and food, pharmaceutical or cosmetic composition comprising the same | |
JPH10298094A (en) | Lipid metabolism-improving preparation | |
Zahid et al. | Antidiabetic properties of the red belt conk medicinal mushroom Fomitopsis pinicola (agaricomycetes) extracts on streptozotocin-induced diabetic rats | |
US20230066836A1 (en) | Antioxidant Extracts and Compositions | |
KR100578626B1 (en) | Composition for functional antioxidant beverage | |
FR3002139A1 (en) | COSMETIC USE OF QUEUINE | |
KR101468921B1 (en) | A method of preparing phytic acid using rice bran, a phytic acid prepared by the same method and a fuctional cosmetics comprising the phytic acid | |
KR20130035594A (en) | Fermented milk comprising extracts of paecilomyces japonica as an active ingredient and method for preparing thereof | |
EP3191106B1 (en) | Composition including silicon-enriched microalgae for therapeutic use | |
KR20160014315A (en) | Cosmetic composition having anti-wrinkle effect containing Nano emulsion of Walnuts and Chestnuts Fermented extract | |
JP2020180071A (en) | Anti-skin aging composition for external use | |
JP2019116456A (en) | Anti-aging skin composition for external use | |
KR20140140338A (en) | Acai berry extracts for improving blood circulation and Hypertension and process for preparation thereof | |
KR100749957B1 (en) | Antioxidant composition containing quercetin and vitamin c and functional food containing the same to inhibit and treat pesticide poisoning or diabetic microvascular complications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |